Public Profile

Samsung Biologics

Samsung Biologics, a leading player in the biopharmaceutical industry, is headquartered in Incheon, South Korea (KR). Founded in 2011, the company has rapidly established itself as a key provider of contract development and manufacturing services (CDMO) for biopharmaceuticals, catering to a global clientele. With a focus on monoclonal antibodies and other biologics, Samsung Biologics offers unique solutions that leverage cutting-edge technology and state-of-the-art facilities. The company has achieved significant milestones, including the completion of its third manufacturing plant, which enhances its production capacity and reinforces its market position. Recognised for its commitment to quality and innovation, Samsung Biologics continues to set industry standards, making it a preferred partner for biopharmaceutical companies worldwide.

DitchCarbon Score

How does Samsung Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

43

Industry Average

Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

25

Industry Benchmark

Samsung Biologics's score of 43 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.

97%

Let us know if this data was useful to you

Samsung Biologics's reported carbon emissions

In 2023, Samsung Biologics reported total carbon emissions of approximately 754,473,000 kg CO2e, comprising 1,209,000 kg CO2e from Scope 1, 5,086,000 kg CO2e from Scope 2, and 528,480,000 kg CO2e from Scope 3 emissions. This marked a significant commitment to sustainability, as the company aims for net zero emissions by 2050 or earlier. To achieve this goal, Samsung Biologics has set ambitious reduction targets: a 32% reduction in direct emissions by 2030 and a 62% reduction by 2040, using 2022 as the baseline year. Additionally, the company plans to reduce emissions from suppliers by 36% by 2030 and 73% by 2040. These initiatives reflect Samsung Biologics's dedication to addressing climate change and enhancing its environmental performance within the biopharmaceutical industry.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2020202120222023
Scope 1
41,793,000
0,000,000
0,000,000
0,000,000
Scope 2
83,014,000
0,000,000
0,000,000
0,000,000
Scope 3
-
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Samsung Biologics's primary industry is Research and development services (73), which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Samsung Biologics is in KR, which we do not have grid emissions data for.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Samsung Biologics is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero

Similar Organizations

Abbvie

US
Chemicals nec
Updated 7 days ago

Amgen

US
Chemicals nec
Updated about 19 hours ago

Genentech

US
Research and development services (73)
Updated 10 days ago

Celltrion

KR
Research and development services (73)
Updated 7 days ago

Coherus BioSciences, Inc.

US
Health and social work services (85)
Updated about 1 month ago

Patheon BV

US
Chemicals nec
Updated 2 months ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers